Factor XI inhibitors
A newer class of anticoagulants that target factor XI or XIa.
Key point
Adding an FXIa inhibitor to standard antiplatelet therapy after acute noncardioembolic ischemic stroke or TIA reduces stroke recurrence without evidence of increased bleeding risk.
From: Factor XIa Inhibitors for Secondary Prevention After Noncardioembolic Stroke: A Systematic Review and Meta-Analysis (Neurology, 2026 Oct 13) ↗Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 5, 17, 6, 9, 16.
All papers from the last 12 months
175 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- AlphaFold3 assisted screening strategy identifying novel coagulation factor XIa inhibitory peptides from deep-sea mussel Gigantidas platifronsBioresour Technol2026 DecPMID 42498013
- Prekallikrein: the catalytic crossroads of inflammation and thrombosisCurr Opin Hematol2026 Nov 1PMID 42755375Review
- SHR-2004, a Humanized Monoclonal Antibody Targeting Factor XI, for Preventing Venous Thromboembolism After Ovarian Cancer Surgery: A Randomized, Active-Controlled Phase 2 StudyAm J Hematol2026 NovPMID 42644221RCT
- Thrombin generation and the pharmacodynamics of oral anticoagulantsPharmacol Ther2026 NovPMID 42628806Review
- Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioningCurr Opin Hematol2026 Nov 1PMID 42348666Review
- FXI and FXII in experimental stroke and FXI in clinical stroke trialsNeurol Res Pract2026 Oct 16PMID 42888464Review
- Anticoagulation in Mechanical Circulatory Support: Contemporary Challenges and Future Directions in Cardiovascular PharmacotherapyCardiol Ther2026 Oct 16PMID 42886412Review
- Anticoagulant Regimen for Nonvalvular Atrial Fibrillation in the Elderly and Frail PopulationAm J Cardiol2026 Oct 15PMID 42448258Review
- Bleeding With Asundexian Versus Placebo in Patients With Noncardioembolic Ischemic Stroke or High-Risk TIA: OCEANIC-STROKE Randomized TrialCirculation2026 Oct 13PMID 42866879
- Factor XIa Inhibitors for Secondary Prevention After Noncardioembolic Stroke: A Systematic Review and Meta-AnalysisNeurology2026 Oct 13PMID 42748394Meta-analysisSystematic review
More cardiology trends
All specialties →Cardiac myosin inhibitors
Drugs such as mavacamten and aficamten for hypertrophic cardiomyopathy.
Remote cardiac rehabilitation
Cardiac rehabilitation delivered at home or through digital tools.
Key point: Exercise-based telerehabilitation probably improves cardiorespiratory fitness in adults with CVD but provides no convincing evidence of an antihypertensive effect.
Inclisiran
An siRNA drug that lowers LDL cholesterol by reducing PCSK9 production in the liver.
Key point: Inclisiran achieves similar LDL-C reductions with biannual dosing, potentially improving adherence, though cardiovascular outcome data are pending.
Colchicine in cardiovascular disease
Colchicine as an anti-inflammatory therapy in coronary and cardiovascular disease.
Key point: Low-dose colchicine has demonstrated modest reductions in cardiovascular events, although results across trials have been inconsistent.
Renal denervation
A catheter procedure targeting renal nerves to lower blood pressure.
Intravascular lithotripsy
Shockwaves delivered through a balloon catheter to crack calcium in arteries.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
"factor XI"[tiab] OR "factor XIa"[tiab] OR abelacimab[tiab] OR asundexian[tiab] OR milvexian[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.